Genfit S.A. (GNFTF)
OTCMKTS
· Delayed Price · Currency is USD
3.540
+0.100 (2.91%)
At close: Dec 27, 2024
Genfit Revenue
In the year 2024, Genfit had annual revenue of 70.69M EUR with 105.01% growth. Genfit had revenue of 9.59M in the half year ending December 31, 2024, a decrease of -32.01%.
Revenue
70.69M EUR
Revenue Growth
+105.01%
P/S Ratio
2.96
Revenue / Employee
392.73K EUR
Employees
180
Market Cap
216.71M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Genfit News
- 19 days ago - Genfit S.A. reports Q1 results - Seeking Alpha
- 19 days ago - GENFIT Reports First Quarter 2025 Financial Information - GlobeNewsWire
- 21 days ago - GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy - GlobeNewsWire
- 27 days ago - GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) - GlobeNewsWire
- 4 weeks ago - GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents - GlobeNewsWire
- 5 weeks ago - GENFIT to Present Latest ACLF Research at EASL Congress 2025 - GlobeNewsWire
- 6 weeks ago - GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F - GlobeNewsWire
- 6 weeks ago - GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 - GlobeNewsWire